Molecular and clinical oncology · 2026
Advances in the molecular mechanisms and clinical applications of LEMD1 in tumor development and progression (Review).
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Xiao-Bo, Wang Xian-Fei, Abdul Karim Sairah Binti
Аннотация
LAP2-emerin-MAN1 (LEM) domain-containing protein 1 (LEMD1), first identified in colorectal cancer in 2004, is a gene that is specifically expressed in the testis. The expression of LEMD1 is minimal in normal somatic cells but high in various types of malignant tumor (such as gastric, prostate, pancreatic and colorectal cancer as well as oral squamous cell carcinoma) due to abnormal promoter demethylation. LEMD1 promotes cell proliferation, invasion and metastasis during tumor progression, making it a potential diagnostic marker and therapeutic target. The present review summarized the research progress of LEMD1 as a cancer-testis antigen in tumor biology. Furthermore, the present review investigated the molecular structure and biological functions of LEMD1, its expression patterns, clinical relevance in various types of tumor, and highlighted current research challenges and future directions.